ALRN-6924

MDM2/MDMX dual inhibitor · Aileron Therapeutics

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for ALRN-6924, covering 2025-02-14 to 2026-03-16. Get the full timeline:

Most recent: Clinical Trial Update: ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors [Phase 1]